You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Clinical trials completed
259 Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + selicrelumab (seli) + gemcitabine+nab-paclitaxel (gem+nabP) or bevacizumab (bev) vs control in MORPHEUS-PDAC, -TNBC and -CRC

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020207016
Dec 20206705
Jan 2021121016
Feb 2021102017
Mar 2021118023
Apr 202111008
May 202111022
Jun 20210010
Jul 2021007
Aug 20210015
Sep 2021108
Oct 202151029
Nov 202178025
Dec 202185012
Jan 20225602
Feb 202280017
Mar 20223607
Apr 20228804
May 20229607
Jun 20225606
Jul 20224603
Aug 20224204
Sep 20221604
Oct 20225203
Nov 20223605
Dec 20225202
Jan 2023102011
Feb 20235403
Mar 20235404
Apr 20236209
May 202360010
Jun 20233209
Jul 20233808
Aug 20233404
Sep 20232802
Oct 20232801
Nov 20234407
Dec 20235400
Jan 20242202
Feb 20243201
Mar 20245203
Apr 202450010
May 20244402
Jun 20245505
Jul 20244002
Aug 202449011
Sep 20244407
Oct 20243009
Nov 20243004
Dec 202454018
Jan 20252609
Feb 2025605
Mar 2025001
Apr 2025005
May 2025005
Jun 2025004
Total27310448